Advasa Holdings, Inc. (ADBT) · Oct 27, 2026 · Delisting
Nasdaq listing deficiency — Below $1.00 minimum bid price for 30 consecutive business days; cure deadline April 19, 2027
Advasa received a Nasdaq deficiency notice after 30 straight business days below the $1 bid-price rule, starting a 180-day cure period.
Advasa is a newly public fintech building an earned-wage-access and payroll-payment platform through its Japanese subsidiary, with ambitions to expand its Payroll DX and payment infrastructure internationally. The immediate issue is listing compliance, not operating performance. Nasdaq says Advasa’s closing bid price stayed below the $1.00 minimum for 30 consecutive business days.
| Item | Filing detail |
|---|---|
| Nasdaq cure period | 180 calendar days |
| Compliance deadline | April 19, 2027 |
| Required trading performance | At least $1.00 bid price for 10 consecutive business days |
| Trigger | Below $1.00 for 30 consecutive business days |
The notice creates a real but not immediate delisting risk. Advasa has until April 19, 2027 to regain compliance, and Nasdaq can confirm compliance if the stock meets the threshold for at least 10 consecutive business days. 〔0〕
A lower-tier transfer is the fallback, not a clean resolution. If Advasa cannot cure the deficiency by the deadline, it may seek transfer to the Nasdaq Capital Market if it satisfies the other listing requirements; otherwise, Nasdaq could issue a delisting determination that Advasa could appeal. 〔1〕
The filing offers no operating fix or concrete remediation plan. Management says it will monitor the bid price and consider available options, but it does not disclose a reverse split, capital action, or other identified measure that would restore compliance. 〔2〕
Bottom line: This is a newly disclosed capital-markets problem layered onto a recently listed growth story. The company has substantial time to cure it, but the filing adds a clear delisting overhang without yet showing how management intends to remove it.
Regain $1 bid price by April 19, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!